Mass flow (life sciences)

Tactical Therapeutics, Inc., Developer of CTO Treatments for Glioblastoma, Selected to Present at MedInvest Oncology Investor Conference December 14-15 in New York

Retrieved on: 
Tuesday, December 13, 2022
Therapy, Recurrence, Glioblastoma, TTI, Conference, Veteran, Bevacizumab, Drug discovery, IP, Patient, OS, Oncogene, Temozolomide, Brain, Cancer, Calcium, Calcium signaling, Survival, RNA transfection, Tactic, Radiation, Safety, Mass flow (life sciences), Burn, GBM, Health, Gene, Pharmaceutical industry, Medical device, Phase

Glioblastoma, the brain tumor that killed Senator Ted Kennedy, Beau Biden and Senator John McCain, is still mostly untreatable.

Key Points: 
  • Glioblastoma, the brain tumor that killed Senator Ted Kennedy, Beau Biden and Senator John McCain, is still mostly untreatable.
  • Recent reports suggest veterans of Vietnam, Iraq and Afghanistan wars who were exposed to burn pits later developed GBM.
  • GBM exhibits debilitating neurological symptoms and suicide rates for GBM patients are higher compared to those with other cancers.
  • Tactical Therapeutics, Inc., is a privately funded company that has developed a patented lead therapeutic, CTO, for glioblastoma and other solid cancers.

PharmAbcine to Participate in BIO-Europe 2022

Retrieved on: 
Monday, September 26, 2022
Therapy, Diabetic retinopathy, Immunology, RIT, Ophthalmology, Neoplasm, Mass flow (life sciences), IND, VISTA, Company, DME, Industry, Glioblastoma, Triple-negative breast cancer, Blood, Myeloid-derived suppressor cell, Anti–vascular endothelial growth factor therapy, KOSDAQ, Clinical trial, Drug development, Research, AMD, Public relations, Globe, MDSC, Pharmaceutical industry, Vaccine, Radioimmunotherapy

DAEJEON, South Korea, Sept. 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participate in the upcoming BIO-Europe 2022 which will take place in Leipzig, Germany on October 24 26, 2022.

Key Points: 
  • DAEJEON, South Korea, Sept. 26, 2022 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks), a clinical-stage biotech company focusing on the development of next generation antibody therapeutics, announced today that the Company will participate in the upcoming BIO-Europe 2022 which will take place in Leipzig, Germany on October 24 26, 2022.
  • This year, more than 4,000 global biopharma executives from more than 60 nations around the globe are expected to participate in the event.The event will also be held virtually on November 2 4, 2022.
  • The Company expects to submit an IND for Phase I ophthalmology clinical trial in the second half of 2022.
  • PharmAbcine also has unique knowhow in the area of the antibody production, early drug development, and clinical development.

ERC Granted FDA Fast Track Designation for Sitoiganap in Patients with Recurrent Glioblastoma

Retrieved on: 
Tuesday, July 26, 2022
Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Priority, Brain, GLOBE, Glioblastoma, Food, GM-CSF, CEO, Gliosarcoma, Epitope, Neoplasm, Fast Track, Epitopoietic Research Corporation, Bevacizumab, MOS, Cancer, Observation, Neuro, ERC, Quality of life, Cell, Review, Immunotherapy, FDA, Patient, Mass flow (life sciences), Overalls, Hope, Cyclophosphamide, Vaccine, Pharmaceutical industry

ISNES, Belgium, July 26, 2022 (GLOBE NEWSWIRE) -- ERC Belgium S.A. (ERC), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Sitoiganap (Gliovac or ERC1671) ERCs cell-based immunotherapy for the treatment of glioblastoma, the most aggressive form of brain cancer.

Key Points: 
  • ISNES, Belgium, July 26, 2022 (GLOBE NEWSWIRE) -- ERC Belgium S.A. (ERC), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Sitoiganap (Gliovac or ERC1671) ERCs cell-based immunotherapy for the treatment of glioblastoma, the most aggressive form of brain cancer.
  • The FDA stated, That Sitoiganap, combined with GM-CSF and cyclophosphamide and bevacizumab, for the treatment of recurrent glioblastoma to improve overall survival meets the criteria for Fast Track designation.
  • Apostolos Stathopoulos, M.D., Ph.D., ERC Belgium President and CEO commented, Receiving Fast Track designation from the FDA reinforces ERCs belief that our cell-based immunotherapy for the treatment of serious cancers represent a major breakthrough.
  • Sitoiganap is for patients suffering from a grade IV glioma (glioblastoma and gliosarcoma) when all other traditional treatments have failed.

ERC Announces Publication of Positive Efficacy Data with Sitoiganap in Patients with Recurrent Glioblastoma

Retrieved on: 
Thursday, June 30, 2022
Cell, Frontiers, Neuro, Patient, ERC, CEO, Glioblastoma, Brain, GLOBE, Gliosarcoma, Cancer, Disease, Mass flow (life sciences), Prognosis, Epitopoietic Research Corporation, Neoplasm, Toxicity, Doctor of Philosophy, Survival, Quality of life, Immunotherapy, Safety, Epitope, Recurrence, MD, Hope, Observation, Pharmaceutical industry, Medical imaging, Medicine

The authors reported striking efficacy and safety of a therapeutic vaccine SITOIGANAP administered to 21 patients with recurrent glioblastoma (rGBM).

Key Points: 
  • The authors reported striking efficacy and safety of a therapeutic vaccine SITOIGANAP administered to 21 patients with recurrent glioblastoma (rGBM).
  • Glioblastoma has a dismal prognosis with half of rGBM patients dying within 8 months of recurrence of the disease.
  • Data presented by the authors show that treatment with Sitoiganap (also called Gliovac or ERC1671) more than doubles median overall survival to 19.6 months.
  • Sitoiganap is for patients suffering from a grade IV glioma (glioblastoma and gliosarcoma) when all other traditional treatments have failed.

SonALAsense Achieves Significant Clinical, Growth and Funding Milestones Toward its Mission to Soundly Defeat Cancer

Retrieved on: 
Tuesday, June 28, 2022
Biotechnology, FDA, Other Health, Health, Radiology, Pharmaceutical, Oncology, Health Technology, Medical Devices, Surgery, Clinical Trials, FDA, Schering-Plough, Bluebird bio, Patient, LinkedIn, Survivor, SBIR, NCI, Diffuse intrinsic pontine glioma, HGG, Senior, Freeman, Patient engagement in Canada, Cell death, Growth, Degenerative disease, Company, MTD, American Cyanamid, Pons, Oxidative stress, Brain, Mass flow (life sciences), Series, High-intensity focused ultrasound, Glioblastoma, Coronavirus Scientific Advisory Board (Turkey), University of Maryland School of Medicine, Maryland School, Clinical trial, Index (publishing), Technology, University, Standard of care, Doctor of Philosophy, Neurosurgery, SDT, Temozolomide, Leadership, Safety, Twitter, ALA, MD, Hope, DIPG, GBM, Pharmaceutical industry, Medical imaging, Medicine

SonALAsense is working on two trials to evaluate the therapeutic potential of SONALA-001 SDT for DIPG and rGBM .

Key Points: 
  • SonALAsense is working on two trials to evaluate the therapeutic potential of SONALA-001 SDT for DIPG and rGBM .
  • The DIPG trial is actively recruiting and the rGBM clinical trial will begin recruiting shortly.
  • SDT utilizes SONALA-001 (a drug) in combination with MR-guided focused ultrasound (a device) to selectively target and kill tumor cells.
  • Follow SonALAsense on Twitter and LinkedIn and visit our website: https://sonalasense.com/
    View source version on businesswire.com: https://www.businesswire.com/news/home/20220628005315/en/

Medicenna Reports Fiscal Year 2022 Financial Results and Operational Highlights

Retrieved on: 
Wednesday, June 22, 2022
CD25, Population, IL-2, Society, Insurance, Forward-looking statement, CAB, Clinical Cancer Research, Clinical trial, IND, Calendar, Biskit, D&O, Board of directors, GBM, Conference, GLOBE, Observation, CEO, SUD, Coronavirus Scientific Advisory Board (Turkey), CD122, NASDAQ, News, Brain, DRS, Board, The Lancet, Industry, FDA, Drug development, American Association, GMP, American Association for Cancer Research, Cohort, MDNA, SAB, Patient, Mass flow (life sciences), Toxic leukoencephalopathy, ID, Infrared spectroscopy correlation table, Immunotherapy, Association, NK, MBA, Research, Company, Cancer, Bifunctional, MHSC, Partnership, EMA, Pharmaceutical industry, Online gambling, Medical device, Airline, Vaccine

TORONTO and HOUSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or “the Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced its financial results and operational highlights for the fiscal year ended March 31, 2022. All dollar amounts are expressed in Canadian currency unless otherwise noted.

Key Points: 
  • TORONTO and HOUSTON, June 22, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (Medicenna or the Company) (NASDAQ: MDNA TSX: MDNA), a clinical stage immunotherapy company, today announced its financial results and operational highlights for the fiscal year ended March 31, 2022.
  • Program highlights for the year ended March 31, 2022, along with recent developments include:
    Throughout fiscal year 2022, Medicenna completed activities associated with GMP compliant manufacturing of MDNA11 the Companys selective, long-acting and novel IL-2 super-agonist.
  • In April 2022 Medicenna presented results from two of its novel preclinical assets at American Association for Cancer Research meeting.
  • Throughout fiscal year 2022, Medicennas MDNA55 program was highlighted in both peer-reviewed publications and at medical conferences.

Plus Therapeutics Reports Positive Clinical Outcomes from ReSPECT-GBM Trial at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting

Retrieved on: 
Monday, June 13, 2022
SNMMI, Adult, UT, Company, Strategic management, Research, Neoplasm, Ependymoma, Mass flow (life sciences), Society of Nuclear Medicine and Molecular Imaging, Perception, Glioblastoma, Society, Cancer, PSTV, GBM, Annual general meeting, Nasdaq, UT Health San Antonio Cancer Center, Therapy, Brain, GLOBE, Patient, Liposome, Radiation, CED, Molecular imaging, Nuclear medicine, Convection, U.S. Securities and Exchange Commission, Safety, Medical imaging, Pharmaceutical industry

AUSTIN, Texas, June 13, 2022 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present positive data on its lead investigational drug, Rhenium-186 NanoLiposome (186RNL), from the Phase 1/2a ReSPECT™-GBM dose escalation clinical trial in patients with recurrent glioblastoma (GBM) during an oral presentation at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2022 Annual Meeting, on June 14 at 10:20 AM PT in Vancouver, British Columbia, Canada.

Key Points: 
  • 186RNLs tumor-killing effects were observed when greater than 100 Gy doses are delivered to greater than 80% of a tumor without dose-limiting toxicity.
  • To date, there have been no significant adverse events during the dose escalation.
  • To treat glioblastoma, the targeted and controlled use of 186RNL is critical for patients as we aim to mitigate brain and whole-body exposure.
  • The Company expects to initiate a Phase 2/registrational trial of 186RNL in patients with recurrent GBM by the end of 2022.

Erasca Reports First Quarter 2022 Financial Results and Business Updates

Retrieved on: 
Thursday, May 12, 2022
People, Senior, Cancer, Lilly, KOL, MD Anderson Cancer Center, R, CRC, Private Securities Litigation Reform Act, G&A, Research, Mass flow (life sciences), U.S. Securities and Exchange Commission, Annual report, KRAS, RAS, Patient, Investment, Insurance, AACR, Form 10-K, Pharmacokinetics, Association, BRAF, Pfizer, COVID-19, SAN, Encorafenib, IND, Industry, Clinical trial, Research and development, CNS, American Association for Cancer Research, Glioblastoma, SHP2, Central nervous system, Safety, EGFR, American Association, Administration, Acquisition, SEC, Cetuximab, Security (finance), CA, CEO, GLOBE, Pharmaceutical industry, Airline

SAN DIEGO, May 12, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the fiscal quarter ended March 31, 2022, and provided business updates.

Key Points: 
  • We also remain on track to file an IND for ERAS-3490 in the second half of 2022.
  • Research and Development (R&D) Expenses: R&D expenses were $27.4 million for the quarter ended March 31, 2022, compared to $12.2 million for the quarter ended March 31, 2021.
  • General and Administrative (G&A) Expenses: G&A expenses were $7.1 million for the quarter ended March 31, 2022, compared to $3.7 million for the quarter ended March 31, 2021.
  • Erasca cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

PharmAbcine to participate in Jefferies Global Healthcare Conference and BIO International Convention

Retrieved on: 
Wednesday, May 11, 2022
Drug development, Anti–vascular endothelial growth factor therapy, IND, Mass flow (life sciences), DME, Company, Neoplasm, VISTA, Jefferies, Patient, Triple-negative breast cancer, Diabetic retinopathy, Immunology, Myeloid-derived suppressor cell, Therapy, Ophthalmology, Clinical trial, Public relations, MDSC, Conference, AMD, Glioblastoma, Research, Phase, Medical device, Pharmaceutical industry, Vaccine

At Jefferies Global Healthcare Conference, Dr. Yoo will hold meetings with registered members of the investor community to look for investment opportunities and to discuss the current trends in drug development and healthcare sector.

Key Points: 
  • At Jefferies Global Healthcare Conference, Dr. Yoo will hold meetings with registered members of the investor community to look for investment opportunities and to discuss the current trends in drug development and healthcare sector.
  • The registered members will include leading global executives, institutional investors, and private equity investors.
  • After the meetings at Jefferies, Dr. Yoo and Dr. Park will participate in BIO International Convention to meet with global pharmaceutical companies.
  • They will introduce PharmAbcine's core technology and pipeline assets to discuss potential licensing and co-development opportunities with global biotechs and pharmaceutical companies participating in the event.

VBL Therapeutics Receives FDA Fast Track Designation for Ofra-Vec for the Treatment of Platinum-Resistant Ovarian Cancer

Retrieved on: 
Tuesday, April 26, 2022
Annual report, Glioma, DSMC, Fast track (FDA), U.S. Securities and Exchange Commission, PFS, COVID-19, Paclitaxel, Twitter, Adult, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, European Commission, Research, Biologics license application, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Food, YouTube, GLOBE, OS, Patient, LinkedIn, TEL, OVAL, Royal commission, Review, Technology, Nasdaq, Therapy, Solution, SEC, Ofranergene obadenovec, NEW, Fast Track, FDA, BLA, Ovarian cancer, Risk, Mass flow (life sciences), VBL, Form 20-F, Cancer, Survival, Pharmaceutical industry, Facebook

We are pleased to receive FDA Fast Track designation for ofra-vec in platinum-resistant ovarian cancer.

Key Points: 
  • We are pleased to receive FDA Fast Track designation for ofra-vec in platinum-resistant ovarian cancer.
  • The lead clinical program for ofra-vec is the OVAL Phase 3 registration-enabling trial in recurrent platinum-resistant ovarian cancer patients.
  • Ofra-vec has received orphan designations for the treatment of ovarian cancer and for the treatment of glioma by the European Commission.
  • The FDA granted ofra-vec orphan designation for the treatment of malignant glioma and fast track designation for the treatment of rGBM and the treatment of platinum-resistant ovarian cancer.